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Abstract
Different pathways have been reported to be involved in platelet–collagen interaction. We have reported that the platelet endothelial form
of nitric oxide synthase (eNOS) and the platelet receptor for type I collagen, p65, are closely associated. But the controlling mechanism
underlying the generation of nitric oxide (NO) by the eNOS has not been fully explored. In this investigation, Western blot analyses of time
course samples with anti-phosphorylated tyrosine, and anti-serine/threonine showed a marked increase in serine/threonine phosphorylation of
eNOS during type I collagen-induced platelet aggregation. Meanwhile, the eNOS activity measured by the conversion of [3H]-arginine to
[3H]-citrulline is significantly decreased. Correlation of type I collagen-induced platelet aggregation and the activity of eNOS in the presence
of the serine/threonine phosphatase inhibitor, okadiac acid and the tyrosine phosphatase inhibitor, vanadate were performed with PRP.
Results show the decrease in eNOS activity by adding okadiac acid correlated with the inhibitory effect on platelet aggregation in a dose-
dependent manner. On the other hand, vanadate significantly inhibits platelet aggregation and also inhibits eNOS activity when the
concentration of vanadate is greater than 2 mM. These results suggest that phosphorylation of serine/threonine and tyrosine residues control
the activity of eNOS through different mechanisms to affect collagen-induced platelet aggregation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Platelets play an important role in the process of homeo-
stasis and thrombosis. Following injury to blood vessels and
in certain pathologic conditions, platelets adhere to the
exposed subendothelial connective tissue (collagen in par-
ticular), aggregate, and release several biologically active
substances. The adherence of platelets to the subendothelial
component collagen has been demonstrated to be a receptor-
mediated event [1–3].
Collagen–platelet interaction involves two groups of
platelet proteins: integrin a2h1 [4] and non-integrin recep-
tors including p65, glycoprotein VI, and glycoprotein IV
(for review see Refs.[5,6]). Many reports have shown that
signal transduction pathways seem different between integ-
rin and glycoprotein VI [7–9]. The signal transduction
pathway for other non-integrin receptors are not known.
We have reported that p65 is associated with endothelial
nitric oxide synthase (eNOS) [10]. Furthermore, we
reported that nitrosylated recombinant 65 kDa proteins fail
to inhibit type I collagen-induced platelet aggregation [11].
The controlling mechanism, however, of eNOS is not
established.
Nitric oxide (NO) produced by various cells (especially
the endothelial cells) was noted to be important in inhibiting
adhesion and aggregation of platelets. Recently, the platelets
themselves have been shown to synthesize NO [12–15].
This supposedly serves to inhibit the recruitment of other
platelets, thereby keeping aggregation under control [16,17].
It is also known that the activity of NO synthase decreases
once platelet aggregation has occurred. In an in vitro model
study, NO has been reported to reduce thrombus growth
[18]. The generation of NO by the platelet could lead to
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regulatory effects within the platelet itself as well as on
elements in the surrounding environment. NO can modulate
certain hemoprotein enzymes in the biosynthetic cascade
that governs the formation of eicosanoid mediators of
thrombosis and hemostasis, including prostaglandin I2 syn-
thase and thromboxane A2 synthase [19].
In the present investigation, we have found that there
is a close association between the activity of eNOS and
the p65 platelet non-integrin receptor. The activity of
eNOS is controlled by serine/threonine and tyrosine phos-
phorylation.
2. Materials and methods
2.1. Materials
Materials used in this investigation included anti-eNOS
(Transduction Lab., Lexington, KY), anti-phosphotyrosine
and anti-phosphoserine/phosphothreonine (Upstate Biotech-
nology, Lake Placid, NY). Type I collagen solution was
purchased from Chrono-Log Corp. (Havertown, PA). All
other chemicals were from Sigma Chemical Co. (St. Louis,
MO), Fisher Scientific (St. Louis, MO), Bio-Rad Lab.
(Hercules, CA), and Pierce (Rockford, IL).
2.2. Preparation of platelet-rich plasma (PRP)
Human blood (nine parts) from healthy volunteers was
collected in polypropylene tubes containing one part 3.8%
sodium citrate after an overnight fast. PRP was prepared by
centrifuging the citrated blood at room temperature for
10 min at 226 g [20]. Whole blood and PRP were exposed
to plastic surfaces or siliconized vessels only. Platelet counts
of the PRP (ranging from 200,000 to 300,000 per mm3)
were determined by phase contrast microscopy (using a
hemocytometer).
2.3. Preparation of type I collagen
Collagen was prepared from human placenta according
to Seyer et al. [21]. The concentration of the collagen
solutions was determined by amino acid analysis after
hydrolysis with 6 N HCl [22].
2.4. Platelet aggregometry
Platelet aggregation was measured by the turbidimetric
method of Born [23] using a Lumiaggregometer (Chrono-
Log).
2.5. Assay of the activity of NOS
Assay of NOS activity by the conversion of [3H]-arginine
to [3H]-citrulline was performed by our established method
[24,25]. The volume of the assay mixture was 100 Al and
contained 50 mM Hepes, pH 7.4, 1 mM dithreithreitol, 1
mM EDTA, 1.25 mM CaCl2, 1 AM leupeptin, and 100 nM
[3H]-arginine (63 Ci/mmol, L-2,3,4,5). The reaction was
initiated by adding the substrate and incubating for 5 min at
room temperature (22 jC). The reaction was stopped with 2
ml 20 mM Hepes, pH 5.5/2 mM EDTA and the mixture
applied to 1 ml columns of Dowex AG50WX-8 (Na +
form), which were eluted with 2 ml of water. [3H]-citrulline
was quantified by a liquid scintillation spectrometer (Pack-
ard Instrument) with 15 ml ScintiVerse BD (Fisher Scien-
tific). A boiled lysate was used as a background control.
Activity was determined by the recovery of the end product,
labeled citrulline, which is produced in molar equivalence to
NO in the supernatant. Activity was expressed as the mean
of picomoles of citrulline formed/number of platelets from
duplicate experiments.
2.6. Western blot
Platelets were harvested by centrifugation after exposure
to type I collagen. Platelet pellets were resuspended in 20
mM Tris–HCl buffer (pH 7.4) containing enzyme inhibitors
(25 AM aprotinin, 25 AM leupeptin, and 1 AM PMSF). The
suspension was sonicated for 20 s at 4 jC and an aliquot of
SDS-PAGE sample buffer was added. The suspension was
then boiled for 3 min and analyzed by 10% SDS-PAGE
[26]. Protein bands were electrophoretically transferred onto
nitrocellulose membrane, followed by treatment with 3%
dried milk in TBS (20 mM Tris–500 mM NaCl–0.05%
Tween 20, pH 7.4) to eliminate non-specific binding. The
nitrocellulose sheet was then washed three times with TBS
and incubated with its respective antibody overnight at 4
jC. After washing three times in TBS, the nitrocellulose
sheet was incubated with a second antibody (peroxidase
conjugated goat anti-mouse IgG, 1/20,000) for 2 h at room
temperature. After three washings with TBS, the nitrocellu-
Fig. 1. Comparison of basal levels of treatments. We have performed
treatments to establish a baseline for the subsequent experiments. We have
three treatments as follows: lane 1, PRP without adding collagen; lane 2,
PRP with PBS but no collagen added; and lane 3, PRP with collagen at zero
time. Platelets were harvested from these treatments, washed with 0.5 ml
PBS, suspended in SDS-PAGE sample buffer, and sonicated for 10 s. These
samples were boiled for 3 min, and analyzed by 7.5% SDS-PAGE. After
transferring onto a nitrocellulose sheet, Western blots were analyzed with
three antibodies (1/1000) as indicated in the figure. The dilution of the
second antibody (peroxidase conjugated anti-goat IgG) was 1/20,000 and
development was with ECL solutions. Changes in band intensities are under
each band and were determined by the Bio-Rad computer program—
Quality One. The data shown are from one experiment which is
representative of two others that gave similar results.
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lose sheet was developed with ECL solution as described by
the manufacturer (Amersham, Arlington Heights, IL) [11].
3. Results
It is well established that NO is involved in collagen–
platelet interaction. But the exact mechanism whereby NO
acts is not firmly established. We have previously reported
that eNOS and p65 co-precipitate using either anti-eNOS or
anti-p65 [11]. We tried to examine whether the association
of these two components could contribute to eNOS activity
during type I collagen-induced platelet aggregation. A time
course correlation between these components during type I
collagen-induced platelet aggregation was made with West-
ern blot analyses through the use of various antibodies
obtained from commercial sources.
We have performed experiments to establish the base-
line in different conditions such as PRP without adding
collagen, PRP with PBS but no collagen added, and PRP
with collagen at zero time. Results showed that there are
no differences in all of these conditions (Fig. 1). We have
also assayed the NOS activity. The results expressed as
meanF S.D. of these three conditions (PRP control without
adding collagen—NOS activity is 2.42F 02, PRP with
PBS but no collagen added—NOS activity is 2.43F 0.15,
and PRP with collagen at zero time—NOS activity is
2.39F 0.15) are quite similar. For the purpose of correlating
the time course of platelet aggregation and changing of
Fig. 3. Western blot analyses. Samples were collected at different times (0, 30, 60, 120, and 240 s) after adding collagen for Western blots with anti-eNOS (1/
1000, left panel), anti-Ser-p/Thr-p (1/1000, middle panel), and anti-Tyr-p (1/1000, right panel). The dilution of the second antibody (peroxidase conjugated
anti-goat IgG) was 1/20,000 and development was with ECL solutions. Changes in band intensities are under each band and were determined by the Bio-Rad
computer program—Quality One. The data shown are from one experiment which is representative of two others that gave similar results.
Table 1
Effect of okadiac acid and vanadate on the activity of platelet NOS
Additions NOS Activity
(pmol/0.45 ml PRP)
PA (%)
PBS 2.51F 0.1 [100] 0
C 0.5 Ag 2.48F 0.3 [99] 80F 5
OA 2 AM+C 0.5 Ag 0.28F 0.1 [11] 5F 2
OA 1 AM+C 0.5 Ag 0.53F 0.3 [21] 40F 3
OA 0.5 AM+C 0.5 Ag 0.64F 0.3 [25] 65F 4
V 4 mM+C 0.5 Ag 0.36F 0.04 [14] 5F 2
V 2 mM+C 0.5 Ag 0.39F 0.2 [16] 5F 3
V 1 mM+C 0.5 Ag 1.43F 0.6 [57] 25F 4
OA 1 AM+V 2 mM+
C 0.5 Ag
0.65F 0.2 [26] 10F 2
OA 0.5 AM+V 1 mM+
C 0.5 Ag
0.48F 0.2 [19] 50F 3
OA 1 AM 1.85F 1.01 [74] 0
V 2 mM 2.66F 0.2 [106] 0
An aliquot of 0.45 ml PRP was incubated with the above listed agents for
10 min. At the end of the pre-incubation, collagen (0.5 Ag) was added to
each tube and incubated for 2 min. The mixture was centrifuged and
washed with PBS. An aliquot of assay buffer (50 Al) was added to each tube
and sonicated for 10 s. Other assay components were added to each tube
and the reaction was initiated with [3H]-arginine. The reaction was
incubated for 5 min at 22 jC and stopped with 2 ml stopping buffer. [3H]-
citrulline was recovered from the reaction mixture by Dowex column.
Radioactivity was assessed by a scintillation counter. Data are expressed as
meanF S.D. of experiment in triplicates. Numbers in brackets are
calculated as percentages of PBS. Platelet aggregation was determined
with a Chrono-Log aggregometer in triplicates. Platelet aggregation (PA %)
was recorded at 2 min after addition of collagen. The data shown are from
one experiment representative of two others that gave similar results. OA,
okadiac acid; V, vanadate; and C, collagen.
Fig. 2. Time course of type I collagen-induced platelet aggregation. Platelet
aggregation was measured with a Chrono-Log aggregometer. PBS (curve a)
and type I collagen solution (0.5 Ag, curve b) were added at the arrows.
Sampling times are 0, 30, 60, 120, and 240 s after adding collagen.
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various parameters, we performed a time course experiment
of type I collagen-induced platelet aggregation (Fig. 2,
curve b). As can be seen, type I collagen-induced platelet
aggregation is time-dependent. After the addition of colla-
gen, platelets undergo shape change and then aggregate. The
response of platelets to the vehicle control (PBS) is shown
in Fig. 2, curve a.
It has been reported that phosphorylation affects the
activity of eNOS [27–30]. We have used the course of
change in phosphorylation of eNOS as the time frame to
guide our sampling during type I collagen-induced platelet
aggregation. Fig. 3 shows the Western blots of anti-eNOS,
anti-phosphoserine/threonine, and anti-phosphotyrosine
samples at different time intervals. As can be seen in the
left panel of Fig. 3, the amount of eNOS protein decreases
about 20% during type I collagen-induced platelet aggrega-
tion. There is a time-dependent increase (two- to three-fold)
in serine/threonine phosphorylation of eNOS during type I
collagen-induced platelet aggregation (middle panel). The
phosphorylation of serine/threonine moieties of eNOS rea-
ches its maximum at 1 min during which time platelets
undergo shape change. There is also a time-dependent
increase (two-fold) in tyrosine phosphorylation of eNOS
(right panel). The increase in phosphotyrosine of eNOS
reaches its maximum at 30 s, which is before platelet shape
changes. These results suggest that type I collagen induces
platelet aggregation and decreases NO production which
may be mediated by the serine/threonine or tyrosine phos-
phorylation of eNOS.
An attempt was made to correlate the eNOS activity and
type I collagen–platelet aggregation by serine/threonine and
tyrosine phosphatase inhibitors. Okadiac acid is a serine/
threonine phosphatase inhibitor and vanadate is a tyrosine
phosphatase inhibitor (Table 1). As shown in the table, there
is a correlation between type I collagen-induced platelet
aggregation and the activity of eNOS. Both were inhibited
by okadiac acid in a dose-dependent manner. On the other
hand, there is no correlation of inhibitory effect of vanadate
on the activity of NOS and type I collagen-induced platelet
aggregation. The combination of low concentrations of both
inhibitors seems to inhibit both the activity of eNOS and
type I collagen-induced platelet aggregation.
To ensure that the serine/threonine and tyrosine phos-
phorylation of eNOS can regulate the activity of eNOS, we
assayed the activity of eNOS by the conversion to [3H]-
citrulline of [3H]-arginine. As shown in Fig. 4, the activity
of eNOS decreased over the time frame of type I collagen-
induced platelet aggregation compared to control samples.
4. Discussion
In the present investigation, we have studied the relation-
ship among the activity of eNOS, phosphorylation of serine/
threonine and tyrosine of eNOS, and type I collagen-
induced platelet aggregation. The results of this study
demonstrate that there is a marked increase in the platelet
eNOS phosphorylation on serine/threonine that correlates
with the inhibition of platelet aggregation. On the other
hand, tyrosine phosphorylation of eNOS slightly changes
eNOS activity. These results were confirmed by using
inhibitors such as okadiac acid and vanadate for serine/
threonine and tyrosine phosphoprotein phosphatases.
We have previously reported that p65 and eNOS co-
precipitate but the time course of the interaction had not
been examined and the nitrotyrosylation of eNOS could not
be demonstrated. The results suggested that nitrotyrosyla-
tion was not a control point for the NO produced during
type I collagen-induced platelet aggregation [11]. In order to
define a mechanism of control for the NO generated, we
tested several possible factors to see whether any of these
might affect eNOS enzyme activity. As we report here, the
activity of eNOS decreases with time during type I colla-
gen-induced platelet aggregation while the intensity of
the phosphorylation of serine/threonine showed marked in-
creases with a slight increase in the tyrosine moieties of the
eNOS. These results support the current paradigm that the
activity of eNOS is controlled by serine/threonine phos-
phorylation and perhaps by tyrosine phosphorylation [30–
32].
Many laboratories have shown that serine/threonine
phosphorylation of eNOS at different sites controls eNOS
activity [31–33]. Michell et al. [34] have reported that
eNOS is primarily phosphorylated on serine and to a lesser
extent on tyrosine and threonine residues. The presence of
Fig. 4. Change in the activity of eNOS during type I collagen-induced
platelet aggregation. Type I collagen-induced platelet aggregation (Fig. 1)
and activity of eNOS are shown in this figure. Columns 1, 2, 3, 4, and 5 are
0, 30, 60, 120, and 240 s after adding collagen, respectively. The activity of
eNOS was measured by the formation of [3H]-citrulline from [3H]-arginine
of triplicate experiments. Hatch bars are PBS controls. Solid bars are
collagen experiments. Data are expressed as meanF S.D. of triplicate
experiments.
T.M. Chiang et al. / Biochimica et Biophysica Acta 1592 (2002) 169–174172
the phosphoprotein phosphatase 1 and other species of
phosphoprotein phosphatases in platelets may play a role
in controlling phosphorylation of serine/threonine of the
eNOS. We have reported that the phosphoprotein phospha-
tase 1 inhibitor, okadiac acid, inhibits dephosphorylation of
serine/threonine residues, inhibits type I collagen-induced
platelet aggregation, and the release of ATP [35,36]. In the
present investigation, we observed that okadiac acid inhibits
eNOS activity which correlates with the inhibition of
platelet aggregation in a dose-dependent manner. This result
is consistent with our earlier finding that okadiac acid, a
serine/threonine protein phosphatase inhibitor, inhibits type
I collagen-induced platelet aggregation [35]. On the other
hand, vanadate, a tyrosine phosphatase inhibitor has an
inhibitory effect on type I collagen-induced platelet aggre-
gation and also inhibits eNOS activity. This result suggests
that the phosphotyrosine phosphatase inhibitor, vanadate,
inhibits type I collagen-induced platelet aggregation and is
different from the phosphoserine/threonine phosphatase
inhibitor, okadiac acid.
Endothelial NOS phosphorylation on serine residues by
protein kinase C (PKC) and cAMP-dependent protein kin-
ase (PKA) has been reported [28,36]. The phosphorylation
of serine/threonine residues on platelet eNOS is probably
controlled by PKC but not by PKA because collagen-
induced platelet aggregation decreases cAMP content but
activates PKC [37–39]. However, serine phosphorylation of
eNOS is essential for the cellular regulation of eNOS
function. It might either increase or decrease its activity,
depending on the kinase and the location of the serine
residue involved.
In summary, the activity of eNOS decreases during type I
collagen-induced platelet aggregation and may be controlled
by different mechanisms involving associations with differ-
ential phosphorylation of specific amino acid residues
located in the eNOS.
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